Pharmacy and Therapeutics Committee Meeting
March 21, 2024
Draft Minutes

Members Present:	**DMAS Staff:**
Lisa Price Stevens, M.D.	MaryAnn McNeil, R.Ph., Pharmacy Manager
Tim Jennings, Pharm.D.	JoeMichael T. Fusco, Pharm.D., MCO Pharmacy Compliance Manager
Ira Bloomfield, M.D.	Rachel Cain, Pharm.D., Clinical Pharmacist
Megan Sarashinsky, Pharm.D.	Usha Koduru, Counsel to the Board, Office of the Attorney General
Olugbenga Obasanjo, M.D.	Kiara M. Jasper, MHA, CPhT. Pharmacy Systems Administrator
Angela Venuto-Ashton, M.D.	Talisha Sheppard, Medical Support Specialist
Michele Thomas, Pharm.D. (for Alexis Aplasca, M.D.)	
Fredrick Moeller, M.D.	

Absent:	**Staff: Magellan Rx Management**
Rachel M. Selby-Penczak, M.D.	Debbie Moody, Pharm.BS, R.Ph., Director Clinical Account Services
Lura Thompson, Pharm.D.	Nancy Eldin, Pharm.D., Pharmacist Account Executive
Sarah Melton, Pharm.D.	David D'Amico, Pharm.D., Pharmacist Account Executive
Carol Forster, M.D..	Lynn Boudreaux, Pharm.D., Rebate Account Executive, Rebate and PDL
	Jeni Hodzic, CPhT, Senior Account Management Specialist
A quorum was present	**Guests:** 48 representatives from pharmaceutical companies, providers, advocates, associations, etc.

Welcome and Comments from Lisa Price Stevens, M.D., Chief Medical Officer and Chairman: Dr. Lisa Price Stevens called the meeting to order and welcomed the members of the Committee and thanked them for their participation in this P&T Meeting. After the introductions, with committee permission, Dr. Price-Stevens turned over chair duties to Dr. Tim Jennings.

Call to Order: The meeting was called to order by Dr. Jennings.

DMAS' Drug Utilization Review (DUR) Board Update: Dr. Rachel Cain provided the DUR update.

December 14, 2023 DUR Meeting:

The Board reviewed 3 new medications - Akeega™ (niraparib and abiraterone acetate), Ojjaara™ (momelotinib), and Vanflyta® (quizartinib). The Board also approved updates to the therapeutic class service authorization criteria for Oral Oncology – Prostate Cancer and Other Neoplasm Drugs. Additionally, the Board reviewed the results of several utilization analyses: the impact reports for the 3 new DUR medications , concurrent use of opioids and benzodiazepines; concurrent use of opioids and antipsychotics; overlaps in opioids, benzodiazepines and antipsychotics; ProDUR reports, RetroDUR reports and utilization analysis reports.

March 14, 2024 DUR Meeting:

The Board reviewed information and Service Authorization (SA) criteria for 6 new medications - Augtyro™ (repotrectinib), Fruzaqla™ (fruquintinib), Iwilfin™ (eflornithine), Ogsiveo™ (nirogacestat), Truqap™ (capivasertib), and Wainua™ (eplontersen)

Hepatitis C Compliance update - Hepatitis C prescribing and compliance data were reviewed by the

DUR Board at the December meeting. Became a 2 meeting discussion.

Additionally, the Board reviewed the results of ProDUR and RetroDUR reports, several utilization analyses: antipsychotic medications in children, antidepressant medications in children, mood stabilizer medications in children, and Overlaps in Antipsychotics, Antidepressants and Mood Stabilizers in Children

The next DUR Board meeting is scheduled for June 13 2024.

The minutes from these meetings can be found at:

https://www.virginiamedicaidpharmacyservices.com/provider/drug-utilization-review/

Housekeeping: Dr. Jennings reminded the members of the conflict-of-interest statement requirements and that the by-laws will be include in all future P&T materials. He informed the committee that Magellan will be presenting an overview of the drugs.

PDL Management

PDL Phase I – New Drug Review *(Therapeutic Class)*

Brand Drugs

1. **Motpoly XR** ***(Anticonvulsants)*** ***(Closed Class):*** Dr. D'Amico presented the clinical information for Motpoly XR. A motion was made and seconded and the committee voted unanimously to consider this drug as PDL eligible.

2. **Zurzuvae™** ***(Antidepressants, Other):***

   Speaker
   - Daphne Ni, PharmD; Medical Account Director, Biogen US Medical

   Dr. D'Amico presented the clinical information for Zurzuvae™. A motion was made and seconded and the committee voted unanimously to consider this drug as PDL eligible.

3. **Rykindo™ (Antipsychotics, Long Acting)** ***(Closed Class)*****:** Dr. D'Amico presented the clinical information for Rykindo™. A motion was made and seconded and the committee voted unanimously to consider this drug as PDL eligible.

4. **Ngenla™ (Growth Hormone)** ***(Closed Class)*****:** Dr. D'Amico presented the clinical information for Ngenla™. A motion was made and seconded and the committee voted unanimously to consider this drug as PDL eligible.

5. **Iyuzeh™ (Ophthalmics, Glaucoma Agents):** Dr. D'Amico presented the clinical information for Iyuzeh™. A motion was made and seconded and the committee voted unanimously to consider this drug as PDL eligible.

6. **Xphozah™ (Phosphate Binders):** Dr. D'Amico presented the clinical information for Xphozah™. A motion was made and seconded and the committee voted unanimously to consider this drug as PDL eligible.

7. **Zepbound™ (Weight Management Agents)** ***(Closed Class)*****:** Dr. D'Amico presented the clinical information for Zepbound™. A motion was made and seconded and the committee voted unanimously to consider this drug as PDL eligible.

Approval of Minutes from September 21, 2023 and October 18, 2023, meetings
Dr. Jennings asked if there were any corrections, additions, or deletions to the draft meeting minutes. With no revisions or corrections, the Committee members approved the minutes as written.

Generic Drugs or New Dosage Forms: Dr. D'Amico noted the following new generics and new dosage forms:

- *(COPD Agents) (Closed Class)*
  - tiotropium (generic for Spiriva®)
- *(Glucocorticoids, Inhaled) (Closed Class)*
  - Breyna™ (generic for Symbicort®)
  - fluticasone propionate Diskus (generic for Flovent® Diskus)
- *(Lipotropics, Statins)*
  - pitavastatin calcium (generic for Livalo®)

A motion was made and seconded and the committee voted unanimously to consider the new generics and new dosage forms as PDL eligible.

Potential New PDL Closed Class:

- ***Immunomodulators, Asthma (Potential New PDL Closed Class)***

  Speaker
  - Ahmad Nessar, PharmD | Medical Affairs Executive Director - DC/MD and VA Ecosystems | Genentech (Xolair®)
  - Katie Rocawich, PharmD, BCCCP Medical Science Liaison |Allergy/Asthma Amgen US Medical Affairs (Tezspire®)

PDL Phase II – Annual Review: Classes with Updates

1. ***Antimigraine Agents, Other (Closed Class):***

   Speaker
   - Jeff Norman, Ph.D. Director, Field Medical - Internal Medicine and Hospital Field Medical Group Pfizer (Nurtec® ODT)
   - Olaide Akingbade, PharmD Medical Outcomes & Science Liaison Mid-Atlantic (DC, VA, NC, SC) US Medical Affairs (Ajovy®)

   Dr. D'Amico presented the Antimigraine Agents, Others clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

2. ***NSAIDs:*** Dr. D'Amico presented the NSAIDs clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

3. ***Opioids: Short Acting (includes combination drugs and lozenges):*** Dr. D'Amico presented the Opioids, Short Acting clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

4. ***Opioid Dependency Treatment Agents (Closed Class) (includes oral buprenorphine):***

   Speaker
   - John Landis, PharmD Medical Science Liaison Pennsylvania (Brixadi®)
   - Cambridge Hampsher, Pharm.D., Medical Outcomes & Value Liaison at Indivior (Sublocade®)

   Dr. D'Amico presented the Opioid Dependency Treatment clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

5. ***Antibiotics, GI:*** Dr. D'Amico presented the Antibiotics, GI clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

6. ***Erythropoiesis Stimulating Proteins:*** Dr. D'Amico presented the Erythropoiesis Stimulating Proteins clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

7. ***Antihyperkinesis/CNS Stimulants (Closed Class):***

   Speaker
   - Jia Li, Pharm D, Regional Medical Manager for Supernus (Qelbree®)
   - Ronnie DePue, PharmD, BCGP, FASCP Senior Director, Health Outcomes Liaison Axsome (Sunosi®)

   Dr. D'Amico presented the Antihyperkinesis/CNS Stimulant Agents clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

8. ***Acne Agents (includes benzoyl peroxide, clindamycin, retinoids & combinations):*** D'Amico presented the Acne Agents clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

9. ***Hypoglycemics: Incretin-Mimetics/Enhancers (includes DPP-IV Inhibitors & Combinations) (Closed Class):*** Dr. Eldin presented the Hypoglycemics: Incretin-Mimetics/Enhancers clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

10. ***Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class):*** Dr. Eldin presented the Hypoglycemics: SGLT2 Inhibitor clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

11. ***Cytokine and CAM Antagonists and Related Agents (Closed Class):***

    Speaker
    - Tara Koehler, PharmD, MPH, BCACP Director, Field Medical Organized Customer Pfizer (Velsipity™)
    - Jacob Brown, PharmD, Health Economics and Outcomes Research Director Bristol Myers Squibb (Sotyktu™)
    - Eory Madera-Miranda, MPharm, Director, Medical Science Liaison-East Biosimilars Medical Affairs (Hadlima®)

    Dr. Eldin presented the Cytokine and CAM Antagonists and Related Agents clinical information. A motion

was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

12. ***Therapeutic Drug Classes Without Updates (Reviewed by the Department):***

- Alzheimer's Agents (Cholinesterase Inhibitors & NMDA Receptor Antagonist)
- Analgesics, Narcotics Long
- Androgenic Agents
- Antibiotics, Topical
- Anticoagulants
- Antifungals, Oral & Topical
- Antihyperuricemics
- Antimigraine Agents, Triptans
- Antivirals For Herpes (HSV) & Influnza
- Bone Resorption Suppression And Related Agents
- Cephalosporins And Related Antibiotics
- Estrogens (Vaginal)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Insulin And Related Agents
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformin
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Ketolides & Macrolides (Adult and Pediatric)
- Long-Acting Reversible Contraceptives (LARCS) (includes long-acting IUDs & injectable)
- Multiple Sclerosis Agents (Closed Class)
- Neuropathic Pain
- Pancreatic Enzymes
- Platelet Aggregation Inhibitors
- Progestational Agents
- Psoriasis Agents
- Quinolones (Otic)
- Quinolones (Second And Third Generations)
- Rosacea Agents, Topical
- Skeletal Muscle Relaxants
- Smoking Cessation

Dr. Eldin noted that the above therapeutic classes had no significant changes since the last P&T Committee review. A motion was made and seconded and the committee voted unanimously for the above-mentioned classes to continue to be PDL eligible.

Comments from the Office of the Attorney General

Ms. Usha Koduru from the Attorney General's office stated that under the Virginia Freedom of Information Act (FOIA), specifically Virginia Code section 2.2-3711, a public body such as the P&T Committee, may go into a closed session for any one of the 51 reasons listed in that statute. The discussion of manufacturer and wholesaler prices is not one of the 51 reasons listed.

She stated the Attorney General strongly supports the principles of open government embodied by the FOIA and believes in the opportunity of the Commonwealth's citizens to fully witness the operation of government.

Federal Law 42 U.S.C. 1396r-8(b) (3) (D) requires such pricing information to be kept confidential. On this point, federal law supersedes the Virginia FOIA. Since the P&T Committee must discuss this pricing information as part of its duties, pursuant to federal law a confidential meeting must occur for the consideration of this pricing information, and she cautioned only this confidential pricing information should be discussed.

Dr. Tim Jennings made a motion for the P&T Committee to resume the meeting in another room to discuss this confidential information regarding prices charged by the manufacturers and wholesalers of the drug classes discussed at this P&T Committee meeting. This confidential meeting is authorized by Federal Law at 42 U.S.C. § 1396r-8(b) (3) (D) that requires this information be kept confidential. We are also going into closed session to request legal advice on the proposed Bylaws pursuant to Virginia code 2.2-3711 8B.

The motion was seconded and unanimously approved by the Committee.

Following the Confidential Session, the Committee members re-assembled on the public session. Dr. Jennings confirmed that to the best of each of the Committee member's knowledge the only information discussed at the confidential meeting was information regarding prices charged by the manufacturers and wholesalers of the drug classes discussed at this P&T Committee meeting as well as legal advice pertaining to the bylaws. As authorized by Federal Law at 42 U.S.C. § 1396r-8(b) (3) (D) that requires this information to be kept confidential.

A motion was made to resume the meeting and for the members to approve the confidential session statement. The motion was seconded and unanimously approved by the Committee.

PDL Changes Effective July 1, 2024

Phase II Annual Review
Dr. Jennings made the following motions that were seconded and approved unanimously by the Committee ***(note the motions are for changes to the current PDL status)****:*

1. ***Stimulants And Related Agents Used For Narcolepsy (Closed Class):*** armodafinil, modafinil and Sunosi are preferred.

2. ***Multiple Sclerosis Agents (Closed Class):*** teriflunomide is preferred. Aubagio is non-preferred.

3. ***Antimigraine Agents Other (Closed Class):*** Qulipta is preferred.

4. ***Immunomodulators, Asthma (Closed Class):*** Fasenra Pen, Fasenra Syringe, Xolair Syringe and Xolair Vial are preferred. Cinqair, Nucala Auto-Injector, Nucala Syringe, Nucala Vial, Tezspire Pen and Tezspire Syringe are non-preferred.

5. ***Macrolides/Ketolides:*** erythromycin base tablet DR is preferred. erythromycin base capsule DR is non-preferred.

6. ***Acne Agents, Topical:*** clindamycin phosphate gel is preferred. sulfacetamide sodium/sulfur cleanser, clindamycin / benzoyl peroxide (ONEXTON) W/PUMP (Authorized Generic) and ZMA clear cleanser are non-preferred.

7. ***Opiate Dependence Treatments (Closed Class):*** Brixadi Monthly and Brixadi Weekly are preferred.

Dr. Jennings made the following motion to make no changes to the following PDL drug classes, which was seconded and approved unanimously by the Committee:

- Alzheimer's Agents (Cholinesterase Inhibitors & NMDA Receptor Antagonist)
- Analgesics, Narcotics Long & Short
- Androgenic Agents
- Antibiotics, GI
- Antibiotics, Topical
- Anticoagulants (Closed Class)
- Antifungals, Oral and Topical
- Antihyperuricemics
- Antimigraine Agents, Triptans
- Antipsoriatics, Topical
- Antivirals for Herpes (HSV) & Influenza
- Bone Resorption Suppression And Related Agents
- Cephalosporins And Related Antibiotics
- Contraceptives, Other
- Cytokine and CAM Antagonists (Closed Class)
- Erythropoiesis Stimulating Proteins
- Estrogens (vaginal)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Incretin Mimetics/Enhancers (Closed Class)
- Hypoglycemics: Insulin and Related Agents
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformin
- Hypoglycemics: SGLT2 (Closed Class)
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Neuropathic Pain
- NSAIDs
- Pancreatic Enzymes
- Platelet Aggregation Inhibitors
- Progestational Agents (Closed Class)
- Quinolones (Otic)
- Rosacea Agents, Topical
- Skeletal Muscle Relaxants
- Smoking Cessation
- Stimulants And Related Agents (Closed Class)

Clinical Criteria and Service Authorization (SA) Forms

The Committee members reviewed the proposed new or revised clinical criteria, including new and updated service authorization fax forms. A Committee member made the following motion to approve new or revised clinical criteria for the following drugs and drug classes, which was seconded and approved unanimously by the Committee:

- New criteria and SA form for Fasenra with revisions requested by the board members
- New criteria and SA form for Nucala with revisions requested by the board members

- New criteria and SA form for Tezspire with revisions requested by the board members
- New criteria and SA form for Xolair with revisions requested by the board members
- New criteria and SA form for Briumvi
- New criteria and SA form for Ocrevus
- New criteria and SA form for Tysabri
- New criteria and SA form for Vyepti
- New Zurzuvae Criteria
- Updates to Narcolepsy Medications SA fax form
- Updates to Topical Antifungal Agents SA fax form

Closing Comments:

The P&T Committee Meetings are moving to quarterly. The next P&T Committee Meeting is tentatively scheduled for June 27, 2024 and the one following that is October 3, 2024. Any weight loss legislative changes from the General Assembly will be discussed at the June meeting. A motion to adjourn the meeting was made and seconded. After a unanimous vote, Dr. Jennings adjourned the meeting.